X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (75) 75
oncology (63) 63
female (57) 57
male (51) 51
aged (50) 50
middle aged (50) 50
adult (38) 38
index medicus (38) 38
cancer (34) 34
chemotherapy (27) 27
lung cancer (22) 22
treatment outcome (22) 22
aged, 80 and over (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
lung neoplasms - drug therapy (19) 19
care and treatment (18) 18
lung neoplasms - pathology (18) 18
antineoplastic agents - therapeutic use (16) 16
carcinoma, non-small-cell lung - drug therapy (15) 15
medicine & public health (15) 15
respiratory system (15) 15
metastasis (14) 14
neoplasm metastasis (13) 13
carcinoma (12) 12
carcinoma, renal cell - drug therapy (12) 12
cisplatin (12) 12
lung cancer, non-small cell (12) 12
analysis (11) 11
antineoplastic agents - adverse effects (11) 11
carcinoma, non-small-cell lung - pathology (11) 11
disease-free survival (11) 11
kidney neoplasms - drug therapy (11) 11
neoplasm staging (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
clinical trials (10) 10
neoplasms - drug therapy (10) 10
research (10) 10
survival (10) 10
therapy (10) 10
carboplatin (9) 9
cell lung-cancer (9) 9
lung neoplasms - mortality (9) 9
maximum tolerated dose (9) 9
metastases (9) 9
pharmacology & pharmacy (9) 9
retrospective studies (9) 9
survival analysis (9) 9
abridged index medicus (8) 8
dose-response relationship, drug (8) 8
drug administration schedule (8) 8
hematology, oncology and palliative medicine (8) 8
kidney neoplasms - pathology (8) 8
mutation (8) 8
patients (8) 8
radiotherapy (8) 8
surgery (8) 8
trial (8) 8
tumors (8) 8
brain neoplasms - secondary (7) 7
carcinoma, renal cell (7) 7
expression (7) 7
gefitinib (7) 7
lung neoplasms - diagnosis (7) 7
prognosis (7) 7
antibodies, monoclonal - administration & dosage (6) 6
article (6) 6
bevacizumab (6) 6
cancer therapies (6) 6
carcinoma, non-small-cell lung - mortality (6) 6
carcinoma, renal cell - pathology (6) 6
cisplatin - administration & dosage (6) 6
combination (6) 6
diagnosis (6) 6
docetaxel (6) 6
erlotinib (6) 6
interleukin-2 (6) 6
medicine, general & internal (6) 6
non-small cell lung carcinoma (6) 6
paclitaxel (6) 6
pharmacology/toxicology (6) 6
product development (6) 6
pyridines - therapeutic use (6) 6
renal cell carcinoma (6) 6
survival rate (6) 6
toxicity (6) 6
urology & nephrology (6) 6
usage (6) 6
adenocarcinoma (5) 5
administration, oral (5) 5
apoptosis (5) 5
apoptosis - drug effects (5) 5
blood-brain barrier (5) 5
brain metastases (5) 5
carboplatin - administration & dosage (5) 5
carcinoma, non-small-cell lung - genetics (5) 5
cell line, tumor (5) 5
central nervous system (5) 5
clinical trials as topic (5) 5
drug resistance, neoplasm (5) 5
drug therapy (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 20, pp. 1919 - 1929
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e17504 - e17504
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2005, Volume 23, Issue 4, pp. 832 - 841
Purpose To validate the Motzer et al prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma (RCC) and to... 
RECOMBINANT HUMAN INTERLEUKIN-12 | INTERFERON-ALPHA | MULTICENTER | ONCOLOGY | PHASE-I TRIAL | TOXICITY | COMBINATION | CANCER | Carcinoma, Renal Cell - mortality | Prognosis | Humans | Middle Aged | Adult | Female | Male | Survival Rate | Aged | Kidney Neoplasms - mortality
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2009, Volume 27, Issue 2, pp. 235 - 241
Journal Article
IET Renewable Power Generation, ISSN 1752-1416, 9/2019, Volume 13, Issue 12, pp. 2261 - 2266
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2016, Volume 34, Issue 7, pp. 661 - 668
Journal Article
Journal Article